CytoSorbents Corp. (CTSO) Begins $1 Million US Army Contract
CytoSorbents is a critical care-focused therapeutic device company using blood purification to modulate the immune system, with the goal of preventing or treating multiple organ failures in life-threatening illnesses. The company's flagship product, CytoSorb, is approved in Europe as a safe and effective extracorporeal cytokine filter. It is designed to reduce the “cytokine storm” that can cause organ failure or death. The company reported today that it successfully completed negotiations and commenced work on the previously announced $1 million Phase II SBIR (Small Business Innovation Research) contract in trauma and burn injury from the U.S. Army. The work, supported by…